The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tanashyan M.M.

Russian Center of Neurology and Neurosciences

Antonova K.V.

Russian Center of Neurology and Neurosciences

Panina A.A.

Russian Center of Neurology and Neurosciences

Painful diabetic polyneuropathy in patients with cerebrovascular diseases

Authors:

Tanashyan M.M., Antonova K.V., Panina A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7): 64‑72

DOI: 10.17116/jnevro202512507164

Read: 1158 times

Buy for 300₽
Contact the author
Table of contents

PAINFUL DIABETIC POLYNEUROPATHY IN PATIENTS WITH CEREBROVASCULAR DISEASES
PAINFUL DIABETIC POLYNEUROPATHY IN PATIENTS WITH CEREBROVASCULAR DISEASES

To cite this article:

Tanashyan MM, Antonova KV, Panina AA. Painful diabetic polyneuropathy in patients with cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7):64‑72. (In Russ.)
https://doi.org/10.17116/jnevro202512507164

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Changes in cerebrometabolic health under the influence of risk factors are realized by the development of vascular disorders, structural and functional disorders of the nervous system. The mutual aggravation of cerebrovascular diseases (CVD), polyneuritic and metabolic disorders leads to the accumulation of pathology. The increasing incidence of diabetes mellitus (DM) and its complications, in particular diabetic pain polyneuropathy (DPN), in combination with CVD require a personalized approach to the management of such patients and determine the choice of targeted drugs with proven efficacy and safety. The article provides an overview of current research on the problem of vascular pathology of the brain and damage to the peripheral nervous system in DM, as well as their own experience in treating patients.

Keywords:

diabetes mellitus
cerebrovascular diseases
diabetic polyneuropathy
chronic pain syndrome
gabapentin

Authors:

Tanashyan M.M.

Russian Center of Neurology and Neurosciences

Antonova K.V.

Russian Center of Neurology and Neurosciences

Panina A.A.

Russian Center of Neurology and Neurosciences

Received:

11.04.2025

Accepted:

16.05.2025

Close metadata

References:

  1. Tanashyan MM, Antonova KV. Cerebrometabolic health: Chapter 5. In: Management of Metabolic Health. Ed. by AS Ametov, M. GEOTAR-Media, 2025;2:119-148. (In Russ.).
  2. Antonova KV, Tanashyan MM, Raskurazhev AA, et al. Obesity and the nervous system. Obesity and Metabolism. 2024;21(1):68-78. (In Russ.). https://doi.org/10.14341/omet13019
  3. Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022;17(1);18-29.  https://doi.org/10.1177/17474930211065917
  4. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus In Russian Federation according to the World Health Organization’s strategy goals. Diabetes Mellitus. 2025;28(1):4-17. (In Russ.). https://doi.org/10.14341/DM13292
  5. Federal State Statistics Service. Healthcare In Russian Federation 2021. Official website. Date of access: 25.01.2025. (In Russ.). https://rosstat.gov.ru/folder/210/document/13218/
  6. Kharisyanova E, Kharisyanov V. Morbidity incidence of the population by the main classes of diseases in the regions of the Russian Federation. Ufa Humanitarian Scientific Forum. 2024;(4):449-460. (In Russ.).
  7. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium; 2021. Available from: https://www.diabetesatlas.org
  8. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.). https://doi.org/10.14341/DM13035
  9. Antonova KV, Tanashyan MM, Romantsova TI, Maksimova MY. Type 2 diabetes mellitus and the clinical course of acute stroke. Obesity and Metabolism. 2016;13(2):20-24. (In Russ.). https://doi.org/10.14341/omet2016220-24
  10. Wang Y, Li Y, Jiao S, et al. Correlation analysis and predictive model construction of metabolic syndrome, complete blood count-derived inflammatory markers, and overall burden of cerebral small vessel disease. Heliyon. 2024;10(16):e35065. https://doi.org/10.1016/j.heliyon.2024.e35065
  11. Tanashyan MM, Raskurazhev AA, Kornilova AA. Cerebrovascular diseases and personalized prevention. Russian Journal of Preventive Medicine. 2021;24(2):76-81. (In Russ.). https://doi.org/10.17116/profmed20212402176
  12. Antonova KV, Tanashyan MM. Diabetic Neuropathy As a Multisystem Process. Effective Pharmacotherapy. 2022;18(30):28-37. (In Russ.).
  13. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.). https://doi.org/10.15829/1728-8800-2019-1-5-66
  14. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. 9th edition. Diabetes Mellitus. 2019;22(1S1):1-144. (In Russ.). https://doi.org/10.14341/DM221S1
  15. Khramilin VN, Strokov IA, Davydov OS, Churyukanov MV. Diagnosis of diabetic polyneuropathy in primary care. Russian Journal of Pain. 2021;19(2):47-53. (In Russ.). https://doi.org/10.17116/pain20211902147
  16. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S185-S194. https://doi.org/10.2337/dc22-S012
  17. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev. Endocrinol. 2021;17(7):400-420.  https://doi.org/10.1038/s41574-021-00496-z
  18. Hicks C. W, Wang D, Matsushita K, et al. Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in US. Adults: A Prospective Cohort Study. Ann Int Med. 2021;174(2):167-174.  https://doi.org/10.7326/M20-1340
  19. Zhu J, Hu Z, Luo Y, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol. 2024;14:1265372. https://doi.org/10.3389/fendo.2023.1265372
  20. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diab Med. 2004;21(9):976-982.  https://doi.org/10.1111/j.1464-5491.2004.01271.x
  21. Galstyan GR, Starostina EG, Yakhno NN, et al. Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. Diabetes Mellitus. 2019;22(4):305-327. (In Russ.). https://doi.org/10.14341/DM9625
  22. Zhang X, Yang X, Sun B, Zhu C. Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. Commun Biol. 2021;4(1):1366. https://doi.org/10.1038/s42003-021-02896-3
  23. Christensen DH, Knudsen ST, Gylfadottir SS, et al. Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort. Diabetes Care. 2020;43(6):1266-1275. https://doi.org/10.2337/dc19-2277
  24. TODAY Study Group. Development and Progression of Diabetic Retinopathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. Diabetes Care. 2021;45(5):1049-1055. https://doi.org/10.2337/dc21-1072
  25. Andersen ST, Witte DR, Dalsgaard EM, et al. Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. Diabetes Care. 2018;41(5):1068-1075. https://doi.org/10.2337/dc17-2062
  26. Callaghan BC, Reynolds E, Banerjee M, et al. Central Obesity is Associated With Neuropathy in the Severely Obese. Mayo Clin Proc. 2020;95(7):1342-1353. https://doi.org/10.1016/j.mayocp.2020.03.025
  27. Callaghan BC, Xia R, Banerjee M, et al. Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status. Diabetes Care. 2016;39(5):801-807.  https://doi.org/10.2337/dc16-0081
  28. Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care. 2017;40(9):1226-1232. https://doi.org/10.2337/dc17-0179
  29. Braffett BH, Gubitosi-Klug RA, Albers JW, et al. Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2020;69(5):1000-1010. https://doi.org/10.2337/db19-1046
  30. Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet. Neurology. 2022;21(10):922-936.  https://doi.org/10.1016/S1474-4422(22)00188-0
  31. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev. Endocrinol. 2018;14(10):591-604.  https://doi.org/10.1038/s41574-018-0048-7
  32. Ding X, Fang C, Li X, et al. Type 1 diabetes-associated cognitive impairment and diabetic peripheral neuropathy in Chinese adults: results from a prospective cross-sectional study. BMC Endocrine Disord. 2019;19(1):34.  https://doi.org/10.1186/s12902-019-0359-2
  33. Zhao L, Mao L, Liu Q, et al. Cognitive impairment in type 2 diabetes patients with and without diabetic peripheral neuropathy: a mismatch negativity study. Neuroreport. 2021;32(14):1223-1228. https://doi.org/10.1097/WNR.0000000000001716
  34. Hostrup SN, Croosu SS, Røikjer J, et al. Altered surface-based brain morphometry in type 1 diabetes and neuropathic pain. Neurosci. 2025;566:39-48.  https://doi.org/10.1016/j.neuroscience.2024.12.033
  35. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017;93(6):1296-313.  https://doi.org/10.1016/j.neuron.2017.02.005
  36. Strand N, Anderson MA, Attanti S, et al. Diabetic Neuropathy: Pathophysiology Review. Curr Pain Head Rep. 2024;28(6):481-487.  https://doi.org/10.1007/s11916-024-01243-5
  37. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nature reviews. Dis Prim. 2019;5(1):41.  https://doi.org/10.1038/s41572-019-0092-1
  38. Eftekharpour E, Fernyhough P. Oxidative Stress and Mitochondrial Dysfunction Associated with Peripheral Neuropathy in Type 1 Diabetes. Antioxidants Redox Sign. 2022;37(7-9):578-596.  https://doi.org/10.1089/ars.2021.0152
  39. Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161(Suppl 1):S65-S86.  https://doi.org/10.1097/j.pain.0000000000001922
  40. Rosenberger DC, Blechschmidt V, Timmerman H, et al. Challenges of neuropathic pain: focus on diabetic neuropathy. J neur trans (Vienna, Austria: 1996). 2020;127(4):589-624.  https://doi.org/10.1007/s00702-020-02145-7
  41. Tao Y, Zhang HY, MacGilchrist C, Kirwan E, McIntosh C. Prevalence and risk factors of painful diabetic neuropathy: A systematic review and meta-analysis. Diab Res Clin Pract. 2025;222:112099. https://doi.org/10.1016/j.diabres.2025.112099
  42. Kwiatkowska KM, Garagnani P, Bonafé M, et al. Painful diabetic neuropathy is associated with accelerated epigenetic aging. GeroScience. 2025;10.1007/s11357-025-01516-w.  https://doi.org/10.1007/s11357-025-01516-w
  43. Cruz-Almeida Y, Sinha P, Rani A, et al. Epigenetic aging is associated with clinical and experimental pain in community-dwelling older adults. Mol Pain. 2019;15:1744806919871819. https://doi.org/10.1177/1744806919871819
  44. Peterson JA, Strath LJ, Nodarse CL, et al. Epigenetic Aging Mediates the Association between Pain Impact and Brain Aging in Middle to Older Age Individuals with Knee Pain. Epigenetics. 2022;17(13):2178-2187. https://doi.org/10.1080/15592294.2022.2111752
  45. Cauda F, Sacco K, D’Agata F, et al. Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in diabetic neuropathic pain. BMC Neurosci. 2019;10:138.  https://doi.org/10.1186/1471-2202-10-138
  46. Tseng, MT, Chiang, MC, Chao, et al. fMRI evidence of degeneration-induced neuropathic pain in diabetes: enhanced limbic and striatal activations. Human Brain Mapp. 2013;34(10):2733-2746. https://doi.org/10.1002/hbm.22105
  47. Wilkinson I. D, Teh K, Heiberg-Gibbons F, et al. Determinants of Treatment Response in Painful Diabetic Peripheral Neuropathy: A Combined Deep Sensory Phenotyping and Multimodal Brain MRI Study. Diabetes. 2020;69(8):1804-1814. https://doi.org/10.2337/db20-0029
  48. Tesfaye S, Selvarajah D, Gandhi R, et al. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 2016;157 Suppl 1: S72-S80.  https://doi.org/10.1097/j.pain.0000000000000465
  49. Dedov II, Shestakova MV, Vikulova OK, et al. Clinical recommendations. Type 2 diabetes mellitus in adults. 2022. (In Russ.).
  50. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact, and risk factors. Pain. 2020;161 Suppl 1:S127-S137. https://doi.org/10.1097/j.pain.0000000000001824
  51. Borbjerg MK, Wegeberg AM, Nikontovic A, et al. Understanding the Impact of Diabetic Peripheral Neuropathy and Neuropathic Pain on Quality of Life and Mental Health in 6,960 People With Diabetes. Diabetes Care. 2025;48(4):588-595.  https://doi.org/10.2337/dc24-2287
  52. Naranjo C, Del Reguero L, Moratalla G, et al. Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. Exp Rev Neurother. 2019;19(12):1201-1209. https://doi.org/10.1080/14737175.2019.1653760
  53. Luneva IYe, Grishina DA, Suponeva NA. Modern Management of Diabetic Polyneuropathy. Effective Pharmacotherapy. 2022;18(10):28-36. (In Russ.).
  54. Stacey BR, Tipton KD, Owen GT, et al. Gabapentin and neuropathic pain states: a case series report. Reg Anesth. 1996;21:65-5. 
  55. Backonja M, Beydoun A, Edwards K.R, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-1836. https://doi.org/10.1001/jama.280.21.1831
  56. Russo M, Graham B, Santarelli DM. Gabapentin-Friend or foe? Pain Pract. 2023;23(1):63-69.  https://doi.org/10.1111/papr.13165
  57. Cole RL, Lechner SM, Williams ME, et al. Differential distribution of voltage-gated calcium channel alpha-2 delta (alpha2delta) subunit mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J Compar Neurol. 2005;491(3):246-269.  https://doi.org/10.1002/cne.20693
  58. Chen J, Li L, Chen SR, et al. The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions. Cell Rep. 2018;22(9):2307-2321. https://doi.org/10.1016/j.celrep.2018.02.021
  59. Chen SR, Zhou HY, Byun HS, et al. Casein kinase II regulates N-methyl-D-aspartate receptor activity in spinal cords and pain hypersensitivity induced by nerve injury. J Pharmacol Exp Ther. 2014;350(2):301-312.  https://doi.org/10.1124/jpet.114.215855
  60. Yu YP, Gong N, Kweon TD, et al. Gabapentin prevents synaptogenesis between sensory and spinal cord neurons induced by thrombospondin-4 acting on pre-synaptic Cav α2 δ1 subunits and involving T-type Ca2+ channels. Br J Pharmacol. 2018;175(12):2348-2361. https://doi.org/10.1111/bph.14149
  61. Hayashida KI, Eisenach JC. Descending Noradrenergic Inhibition: An Important Mechanism of Gabapentin Analgesia in Neuropathic Pain. Adv Exp Med Biol. 2018;1099:93-100.  https://doi.org/10.1007/978-981-13-1756-9_8
  62. Chen G, Zhang YQ, Qadri YJ, et al. Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. Neuron. 2018;100(6):1292-1311. https://doi.org/10.1016/j.neuron.2018.11.009
  63. Rosa AS, Freitas MF, Rocha IR, Chacur M. Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. Eur J Pharmacol. 2017;799:111-117.  https://doi.org/10.1016/j.ejphar.2017.02.012
  64. Ahmad KA, Shoaib RM, Ahsan MZ, et al. Microglial IL-10 and β-endorphin expression mediates gabapentinoids antineuropathic pain. Brain Behavior Immun. 2021;95:344-361.  https://doi.org/10.1016/j.bbi.2021.04.007
  65. Cheli VT, Santiago Gonzalez DA, Namgyal Lama T, et al. Conditional deletion of the L‐type calcium channel Cav1.2 in oligodendrocyte progenitor cells affects postnatal myelination in mice. J Neurosci. 2016;36:10853-10869. https://doi.org/10.1523/JNEUROSCI.1770-16.2016
  66. Camara CC, Araujo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats. Neurosci Lett. 2015;607:52-58.  https://doi.org/10.1016/j.neulet.2015.09.021
  67. Wiffen PJ, Derry S, Bell R.F, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. https://doi.org/10.1002/14651858.CD007938.pub4
  68. Danilov AB, Zharkova TR. Farmakoterapiya gabapentinom bolevogo sindroma pri diabeticheskoy polinevropatii. Consilium Medicum. 2009;11(2):47-49. (In Russ.).
  69. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9,6.  https://doi.org/10.1186/1471-2377-9-6
  70. Ko YC, Lee CH, Wu CS, Huang YJ. Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(11):e14576. https://doi.org/10.1111/ijcp.14576
  71. Sagar TV, Yatish B. Safety and efficacy of duloxetine versus gabapentin in painful diabetic polyneuropathy. Int J Comp Adv Pharmacol. 2022;7(4):223-227.  https://doi.org/10.18231/j.ijcaap.2022.042
  72. Shchepankevich LA, Tanashyan MM, Nikolaev YuA, et al. Painful diabetic polyneuropathy: focus on life quality improvement of patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):76-79. (In Russ.). https://doi.org/10.17116/jnevro201911905176
  73. Tedeschi A, Larson MJE, Zouridakis A, et al. Harnessing cortical plasticity via gabapentinoid administration promotes recovery after stroke. Brain. 2022;145(7):2378-2393. https://doi.org/10.1093/brain/awac103
  74. Khalid Z. Cost-effective pharmacological approaches to poststroke recovery and enhanced neuroplasticity: highlighting discoveries both old and new! Ann Med Surg. 2023;85(4):639-641.  https://doi.org/10.1097/MS9.0000000000000246
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.